Ashwani Sood

Featured in: Favicon

frontiersin.org Favicon

biomedcentral.com (+1) Favicon

snmjournals.org Favicon

europeanurology.com Favicon

onlinelibrary.wiley.com Favicon

jnm.snmjournals.org

Articles

177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial

Jan 7, 2025 | jnm.snmjournals.org | Swayamjeet Satapathy |Piyush Aggarwal |Ashwani Sood |Kunal R. Chandekar

177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant 177Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →